Human Papillomavirus 16 (HPV 16) and HPV 18 Antibody Responses Measured by Pseudovirus Neutralization and Competitive Luminex Assays in a Two- versus Three-Dose HPV Vaccine Trial

Correlation between direct ELISA, single epitope-based inhibition ELISA and Pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine

(2011) Francis J. Dessy et al.   Human vaccines & immunotherapeutics

Multiplexed Serologic Assay for Nine Anogenital Human Papillomavirus Types

(2010) D. Opalka et al.   Clinical and Vaccine Immunology

Comparison of the immunogenicity and safety ofCervarix™ andGardasil®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years

(2010) Mark H. Einstein et al.   Human vaccines & immunotherapeutics

Prevalence of Human Papillomavirus 16 and 18 Neutralizing Antibodies in Prenatal Women in British Columbia

(2009) M. Krajden et al.   Clinical and Vaccine Immunology

Immunogenicity Testing in Human Papillomavirus Virus‐Like‐Particle Vaccine Trials

(2009) John T. Schiller et al.   JOURNAL OF INFECTIOUS DISEASES

Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women

(2008) Troy J. Kemp et al.   VACCINE

HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine

(2008) Elmar A. Joura et al.   VACCINE